Advertisement

Topics

Companies Related to "Gene therapy could eliminate drug side effect Parkinson" [Most Relevant Company Matches] RSS

06:07 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Gene therapy could eliminate drug side effect Parkinson" found in our extensive corporate database of over 50,000 company records.

Showing "Gene therapy could eliminate drug side effect Parkinson" Companies 1–25 of 5,200+

Extremely Relevant

Tosk Inc.

Tosk was founded in 1998 to discover new drugs for genetic diseases and cancer. The original technology, in part licensed from Stanford University,StealthGene and Targeted Gene Delivery technologies. In the process, Tosk discovered and perfected the Optimizing Marketed Drugs side-effect-reducing drugs.Tosk's current drug discovery and development efforts focus on applying the OMD approach to disco...


BioMedica Inc.

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.Oxford BioMedica’s products use genes as the mediators of a therapeutic effect and/or immune response...

Gene Therapy Systems (GTS)

Gene Therapy Systems, Inc. (GTS) designs, develops and commercializes gene therapy products along with other molecular biological reagents for scientists specializing in gene therapy research. GTS is the only company in the biotechnology reagent business that primarily focuses on gene therapy related products.


MeiraGTx

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing potential treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also developing potential treatments for xerostomi...

Relevant

MeiraGTx Limited

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing potential treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also developing potential treatments for xerostomi...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

Talee Bio, Inc.

Talee Bio is a development stage biopharmaceutical company focused on developing gene therapy products for the treatment of cystic fibrosis. The company is developing two inhaled gene therapy drug candidates to treat all cystic fibrosis patients: TL-101, a recombinant AAV-based gene therapy, and TL-102, a lentivirus gene therapy. The company was founded by...

Neurologix

Neurologix, Inc., a leader in the development of innovative therapies for the brain and central nervous system, utilizes gene therapy and other novel technologies. The central nervous system ("CNS") is a new and particularly exciting target for gene therapy because its unique properties prevent the successful treatment of many neurological disorders by conventional means such as drug therapy and s...

Karolinska Institute

The primary objectives of the European Society of Gene Therapy (ESGT) are to promote basic and clinical research in gene therapy, to promote education and the exchange of information and technology related to gene transfer and therapy and to serve as a professional adviser to the community and to the regulatory bodies in Europe.

Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process d...

Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

REPLICor Incorporated

REPLICor is focused on discovering and developing a technology based upon the biological mechanisms of the initiation of DNA replication. Notwithstanding its focus, the company has access to a broadly applicable technology for the fields of gene therapy vectors, novel therapeutics and drug discovery tools. The company is currently working in three programs: i) Gene Therapy involving a platform tec...

Myonexus Therapeutics

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb girdle muscular dystrophies (LGMDs) based on research at Nationwide Children’s Hospital, a leader in neuromuscular gene therapy discovery and translational research. Myonexus Therapeutics’ pipeline includes three clinical stage g...

Akouos

Akouos is a precision genetic medicine company developing gene therapies that restore and preserve hearing. Leveraging its adeno-associated viral vectors (AAV)-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in...

Voyager Therapeutics, Inc.

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniqu...

Amsterdam Molecular Therapeutics B.V

AMT, founded in 1998 and based in Amsterdam, is a leader in the development of human gene based therapies. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This safe and efficacious proprietary platform offers a unique manuf...

MOLOGEN AG

MOLOGEN is specializing in selected areas of Molecular Medicine. Our areas of competence are gene expression, gene therapy and bioinformatics. We are dedicated to the development of DNA expression and delivery technologies for human and veterinary applications, leading to products for gene therapy, and prophylactic and therapeutic DNA-based vaccines

Placon Therapeutics

Placon Therapeutics is a biotechnology company developing next-generation novel platinum medicines designed to improve the efficacy and side effect profile of today’s cytotoxic medicines that are widely used in cancer treatment. The company’s albumin-conjugating platinum drug candidates have long circulating half lives and preferentially accumula...

Dimension Therapeutics

Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Launched by Fidelity Biosciences in 2013, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its adeno-associated virus (AAV) therapeutic discov...

RheoGene Inc

RheoGene is developing the RheoSwitch® Therapeutic System (RTS) for cell and gene therapy. RTS delivers therapeutic gene products in the patient to the right place, at the right time, and at the right dose. Despite advances in the understanding of the genetic and molecular basis of disease, there are no approved gene therapy products on the market today, in part because of the unmet need for effi...

ADVANCED CELL & GENE THERAPY, LLC

ADVANCED CELL & GENE THERAPY, LLC, is a consulting firm serving biotechnology companies, clinical laboratories, and biotechnology investors. We provide practical, experienced guidance in development, GMP/GTP manufacturing, and regulatory compliance, as well as comprehensive scientific and technical strategic analysis of business opportunities in cell, gene and tissue therapies.

9zest

9zest’s mission is to enhance quality of life by leveraging neuroplasticity principles through physical therapy, occupational therapy, yoga, speech therapy and meditation for debilitating conditions such as Parkinson’s, Stroke, and Chronic Pain.

Transgene

TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited diseases. The Company's proprietary technology platform consists of five vector families including three of viral origin - adenovirus, retrovirus, vaccinia virus - and two of non viral origin - cellula...

Midway Pharmaceuticals

Midway Pharmaceuticals is an emerging pharmaceutical company focused on developing proprietary drugs for the treatment of gastrointestinal diseases. The company’s platform technology capitalizes on the finding that certain high molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the...

The Parkinson Alliance

The Parkinson Alliance is the umbrella organization for the Parkinson's Unity Walk. The Kingston, NJ-based national non-profit organization is dedicated to raising funds to help finance the most promising research to find the cause and cure for Parkinson's disease. Through the generous operational support of The Tuchman Foundation and our numerous partnerships, 100 percent of all individual donati...


More From BioPortfolio on "Gene therapy could eliminate drug side effect Parkinson"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks